Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
Status:
Recruiting
Trial end date:
2024-02-04
Target enrollment:
Participant gender:
Summary
The purpose of our prospective monocentric, randomized, controlled trial is to evaluate the
effects of intravenous lidocaine on gas exchange and inflammation in acute respiratory
distress syndrome (ARDS) due or not to Covid-19 pneumonia.
Half of the patients will receive intravenous lidocaine and the other half will receive
intravenous NaCl 0,9 % as placebo.